Reddit Posts
Small-cap earnings jam on Nov 14: which names are on your screen?
Earnings Week Breakdown: What’s Coming Friday Through Tuesday (NXXT, NRXP, CAN and more)
Two Potential Runners in the Pennystock Space
Nice risk to reward swing trade setup
Update on $BTCY, Volume is picking up nicely!
Biotricity does it again . They are up and coming
It’s so frustrating to have knowledge of a product that is used at your work and you try to let others now about it , but when you do you get accused of spamming. How the heck can you let others know about the product and company without spamming?
Biotricity is on the move , making more and more moves in the right direction
Biotricity Btcy hit a floor , many fda approved devices with CPT codes out.Y over y growth. Q over Q growth, then their is this
Biotricity hit a floor, many FDA approved devices out and selling. CPT codes in place .Any buying pressure and it’s off to you he races
Biotricity news out, will make millions just like irythum.
Biotricity ( $BTCY ) Just Reported Strong FYQ3 Results and Guidance. Validation of Bioflux device saving man's life in a local news story.
Biotricity ( $BTCY ) Just Reported Strong FYQ3 Results and Lays Out Plans for a Breakout Year Ahead. $2.67/share.
Biotricity ( $BTCY ) the Future of Cardiac Care and the Impact of the Recent FDA 501(K) Clearance for Biotres. Here's why I think it more than doubles from here.
Biotricity ( $BTCY ) Exceeds Last Year’s Revenues Already in Fiscal H1 and is anticipating FDA approval for Biotres any day now
BTCY starting to bounce now, RSI (14) at 36.25 and a gap above to fill. They are ringing the opening bell today as well. On news watch...
Updated report $BTCY looks like an opportunity here
$ BTCY Triple Digit Revenue Growth and a Strong Med Tech Pipeline at Biotricity $BTCY Recent NASDAQ Up-list
Triple Digit Revenue Growth and a Strong Med Tech Pipeline at Biotricity (BTCY) Recent NASDAQ Up-list
Mentions
I'm still holding FUNFF and BTCY lmao nothing scares me
Coward. I'm still holding onto BTCY and FUNFF
I used to invest in some very simialr funds, but have now switched to some ETF's that are offering yeild like [BTCY.TO](https://BTCY.TO) if your in the Canadian market as I like the near projections for BTC and the fund manages covered calls. Another fav is [LBS.TO](https://LBS.TO) again being from Canada this split fund Class A has been very stable producing a great yeild and keeps close to the NAV. I do hold many other tickers but these R 2 of my favs. JMHO
With BTC and ETH pumping I’m surprised the Canadian ETF haven’t seen much actions (BTCY.B ETCY.B). Thoughts?
With BTC and ETH pumping I’m surprised the Canadian ETF haven’t seen much actions (BTCY.B ETCY.B). Thoughts?
BTCY, ETHY covered calls + ETFs in a tax feee account? What could go wrong
BTCY is 9.16% yield, quit fuckin around lol
Biomedical has been popping off lately. $NMTC has been running, but it's already up 50% since I got in. $BTCY has been going down (I'm under 40%),fingers crossed it will gain back. Not sure why this is happening.
REDWOOD CITY, CA / ACCESSWIRE / January 26, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists' patient use - Bioflux((R)) and Biotres(TM) . The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients. Commenting on the agreement, Biotricity Founder, Chairman and CEO Waqaas Al-Siddiq, Ph.D., said, "The future of healthcare lies with new, state-of-the-art technology that produces a more efficient and higher quality of care through remote care. That means tech that is specially designed for smart remote monitoring of individuals using digital/wireless and cloud-based technology with seamless integration with all platforms and devices. "Our Bioflux and Biotres solutions address a market valued at $6 billion, and we fully expect to capture an increasing share of this growing marketplace," Dr. Al-Siddiq added. "We are delivering cardiac care remotely, 24/7 and in real-time as needed, with technology that rivals existing standard of care solutions. Long term, we are confident our technology, and the lifestyle improvements it encourages will bend the curve of growing rates of heart disease." Left, Biotricity's Bioflux(R) provides real-time active monitoring of ambulatory patients' ECG information. Right, Biotricity's Biotres is a revolutionary connected holter wearable. About Biotricity Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Hey /u/Bcl3018 - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
Adding $SYTA to my watchlist. Do you have a timeline for when 1.30+ on $BTCY?
been seeing some other things on $BTCY. thanks for the TA. good r:r imo. do you have any thoughts on the fundamentals?
funny you say that, I was just reading abt the company because of this post & I came across this news - "Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has signed a distribution agreement with one of the Top 10 US medical device distributors . to distribute its cardiac monitoring solutions, Bioflux and Biotres. "Our focus as a company is on advancing our product development and commercialization to establish Biotricity as the all-in-one, go-to solution for cardiac diagnostics and disease management. We are focusing on building relationships with established organizations with unprecedented leadership in the industry. We believe this partnership will be instrumental in advancing the availability of our solutions, expanding our supply chain, and supporting our growth. Over the next couple months, we will be providing further details on this partnership as we begin our rollout." With the commercialization of its Bioflux and Biotres products, Biotricity has increased its total addressable market from $1 billion to approximately $6 billion." \---- The most interesting part of that news release was the, "Biotricity has increased its total addressable market from $1 billion to approximately $6 billion." So, no, I do not think it is overvalued. But, as I have said before, I am not a pro at this stuff haha
BTCY looks like it might have bottomed
Hey /u/Bcl3018 - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
Hey /u/Bcl3018 - I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
Here you go Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022. Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks." Q1-FY23 Financial Highlights: Revenue totaled $2.1 million. Gross profit totaled $1.2 million. Gross profit margins were 60% and consistent with the full year FY22. Net loss totaled $5 million or $0.098 per share; adjusted loss per share, a non- GAAP measure, was $0.085 per share after removing certain non-recurring expenses. Operating Highlights for the FY22 to Date: After receiving FDA 510(k) clearance in January 2022, in April 2022, Biotricity officially launched wireless wearable holter patch device, Biotres, a revolutionary holter technology. Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem. Launched Bioheart, one of the first heart rhythm recorders and personal heart lifestyle solutions. Expanded our network to cover 29 states with over 2,000 physicians using our product. Full details of the Company's financial results will be filed with the SEC on Form 10-Q by visiting www.sec.gov.
Stock|American Well Cor... ($AMWL)|Biotricity Inc ($BTCY) -|-|- 1 Day Change|+0.8%|+5.4% 1 Week Change|+6.1%|+23.1% 1 Month Change|+7.3%|+50.0% 1 Year Change|-57.8%|-60.2% 5 Year Change|NA|-46.3% 10 Year Change|NA|NA Analyst Target|$5.2 (+34.1%)|$4.2 (+256.4%) Current Sentiment|Neutral|Neutral Want more info? Just reply with command + ticker: 1. status - short-term trend 2. funda - company fundamentals 3. zoomout - long-term trend 4. macro - macro trends (No ticker required) 5. vs - Compare performance of any two stocks/indices e.g AAPL vs TSLA, GOOGL vs SPY 6. help - see list of commands Examples: u/askstockbot status AAPL, u/askstockbot TSLA vs GOOGL
u/askstockbot BTCY vs AMWL
Biotricity receives FDA clearance for Bioflux® Software II System The software significantly improves workflows for analysis, increasing efficiency and reducing costs AUGUST 04, 2020 | BY BIOTRICITY REDWOOD CITY, Calif., Aug 04, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has received a 510(k) clearance from the FDA for its Bioflux Software II System. The software is engineered to improve workflows and reduce analysis time from 5 minutes to 30 seconds. ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events for clinical intervention, highlighting the necessity of driving operational efficiency. This improvement in analysis time reduces operational costs. This allows the company to continue to focus on exceptional customer service and industry leading response times to physicians and their at-risk patients. Additionally, these advances mean we can focus our resources on high-level operations and sales to help drive greater revenue. “We are thrilled to receive this FDA clearance. The system further expands the diagnostic capabilities of our Bioflux device and positions Biotricity as a leader in the fast-growing remote patient monitoring market,” said Waqaas Al-Siddiq, CEO of Biotricity. “The increase in efficiency permits us to scale more quickly as we look forward to additional product launches for the upcoming year.” The FDA clearance will continue to amplify Biotricity’s presence in the remote patient monitoring market, which is expected to reach $1.8 billion by 2026.
(NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced a significant milestone of recording and analyzing over 2 billion heartbeats for Atrial Fibrillation (AFib), the most common type of cardiac arrhythmia and a leading cause of stroke.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. We don't allow discussion of low market cap (less than 500mm) tickers to prevent pump & dump spam and scammers.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. Message /u/zjz if they're above 500 million-ish market cap and not related to crypto/pennies/OTC.
You have options. You can expose yourself to certain cryptos in the stock market (ETHY, BTCY). IMO, there are 10 or less coins that are worth holding. If good news today, all the DeFi coins (Aave, Compound, Synthetix) are going to take off like a mothafucka, followed by Eth, BTC, MATIC, ADA, Solana. Dont waste time on the meme coins and shit coins.
Looking at BTCY. The price is under $2 a share. I know they specializes in heart medicine. Do you think it’s a good buy?
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: BTCY. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I love Biotech, it’s the Wild West. One of my favorite long term plays is a Technology as a service play, Biotricity $BTCY. Look into it; their sales are crushing it, plus a network effect from having the medical providers join their network. Also very sticky, good product.
The divvys on ETHY and BTCY are pretty wild
Look into Covered Call ETF's with yields in Canada. Quite a few tickers. Don't go full into ETHY or BTCY but if coins keep crapping over the weekend getting in for under $5 is a steal (ETHY's 20% - 30% CC strategy is nice, and can hold in TFSA). DGS and BK are good pairings if you don't have Canadian bank exposure. Gotta be willing to go long on shit like that right now in uncertainty but the temporary dips usually revert quickly.
You ask for non-tech stocks and 1/3 of the responses suggest tech. Hmm. I will suggest IGT and RFP. Maybe some BTCY if you like speculative medical.
Big breakout on the daily chart for BTCY, a Technology as a service stock with great fundamentals that’s solving a big problem. I really like this stock.
Biography (Btcy) news letter to share holders The Company believes that it is "well-positioned for 2022." Letter highlights milestones, products roadmap, growth strategy and 2022 goals REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development. Highlights from the shareholder letter include: • Recent uplisting to Nasdaq that the Company believes will help further attract a larger pool of sophisticated institutional investors, and a potential increase in liquidity and visibility • Commercialization of the personal medical 3-devices kit, Biokit, for integration into the Biotricity ecosystem • Record quarterly revenue of $1.81 million for its 2022 fiscal year's second quarter ended September 30, 2021, up 143% year-over-year - its tenth consecutive quarter of triple-digit year-over-year growth • The product roadmap for Bioflux®, Biotres, Biocare® Telemed, Biokit, and Bioheart • The Company's 2022 goals including launching new state-of-the-art cardiac monitoring solutions and software services. Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity commented, "We had a historic second quarter that saw revenue increase 143% YoY, the strengthening of our balance sheet, and uplisting to Nasdaq which has boosted our exposure to investors worldwide. We've made great strides in each vertical we targeted over the year and are well-positioned to continue the execution of our overall growth plan for 2022. We seek to take telemedicine to a new, next-generation level of cost-effectiveness as well as disrupt the cardiac care landscape by reducing patient care costs with improved patient outcomes." The Biotricity December 2021 Shareholder Letter can be viewed at https://www.biotricity.com/wp-content/uploads/2016/09/Biotricity_Letter-To-Shareholders-Dec21.pdf
Buying Btcy , biotricity Biotricity (NASDAQ:BTCY) is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Sold some ATER for a fat profit. Bought BTCY and RFP. I don't think either will be hurt by a Chinese meltdown. Then I bought back my ATER at a much cheaper price. This suckered is volatile as tnt.
**Ticker Added BTCY** Spam: True Last Seen Market Cap: 150187900.0 Is SPAC: False